As part of the Unitaid hepatitis C portfolio investment in prevention of hepatitis C among key populations in LMICs (HepC3P project), PATH will collaborate with its research partner to conduct a study in Ho Chi Minh City and Nghe An province in Vietnam in order to assess the values and preferences, feasibility, effectiveness and cost-effectiveness of delivering long-acting depot buprenorphine (LADB) as treatment of opioid dependence.

We are seeking an agency to import buprenorphine (both long-acting depot and sublingual forms) upon obtaining the study approval granted by the Vietnam Ministry of Health (MOH). It is expected that the study approval granted by the Vietnam Ministry of Health (MOH) in early September 2024. Detailed SOW and proposal requirements are in the attached RFP#2024-044 (in English and Vietnamese).

If you can provide this service, please submit a detailed proposal and qualified profile no later than 5:30 PM on 09th Aug 2024, Hanoi time.

Proposals received after 5:30PM, 09/08/2024 Hanoi time are ineligible.

Organization: PATH
Location:
Application deadline: 2024-08-09
Send application to: [email protected]; [email protected]